Wednesday, October 18, 2017 2:19:05 AM
The Market Opportunity in Oral Mucositis
Brilacidin
With the company approaching next week's final patient follow-up visit and the conclusion of its Phase 2 trial of Brilacidin as a promising preventative treatment for Oral Mucositis (OM) (see NCT02324335 and the highly encouraging interim results), we thought it appropriate to share some data on the overall OM market opportunity.
A large unmet need exists in treating OM as discussed in earlier blogs, accessible here and here. There is no approved preventive or curative treatment for OM. Current treatments for OM, and most therapies in clinical trials, are largely palliative in nature, with few interventions showing clinical benefit. The most common management protocol for OM is the use of mouthwash or gels.
In December 2004, the FDA approved Amgen’s IV-administered Kepivance (palifermin) for the treatment of OM limited to bone marrow cancers. In the primary efficacy study, the median duration of OM (WHO grade 3 and 4) was shorter (three days vs. nine days) in patients receiving palifermin.
Head and Neck Cancer (HNC) patients -- comprising an estimated 65,000 newly diagnosed cases in the U.S. alone in 2017, and an estimated 700,000 worldwide (source: GLOBOCAN) -- are at greatest risk of developing OM (a 90 to 100 percent rate of occurrence). By 2030, the global incidence of HNC cases is expected to exceed 1 million per year. Moreover, between 25 and 60 percent of cancer patients, regardless of cancer type, also will experience OM during the course of their chemo/radiotherapy.
Estimates vary as to the market size (in dollars) of an effective OM treatment, for HNC-only patients, across major markets (U.S., Europe and Japan), ranging between $500 million and $1.5 billion on an annual basis (sources: GlobalData; Redington Inc., pdf). One company in the OM space projects the worldwide OM market opportunity to be as high as $2.6 billion annually.
The completion of Innovation Pharmaceutical’s Phase 2 study of Brilacidin-OM will mark an important step towards the company’s goal of potentially developing the first-ever preventative treatment for OM.
Reporting of topline results is anticipated to occur this quarter.
Good luck and GOD bless,
George
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM